MOESM3 of The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
2020-01-03T04:55:33Z (GMT) by
Additional file 3: Figure S3. Calreticulin-mutant cells are not hypersensitive to LCL-161. (A, B) Resazurin-based cell viability assay showing L929 cells transduced with the Calreticulin (CALR) mutations representing empty vector (EV), wild-type CALR (CALRWT), deletion (CALRDEL) or insertion (CALRINS) (A) containing thrombopoietin receptor (MPL) and (B) without MPL treated with increasing concentrations of LCL-161 for 48 h. **P < 0.01, ***P < 0.001 2way ANOVA. (C) Western blot for cIAP1/2, XIAP, and β-Actin as a loading control in CALRWT, CALRDEL, CALRINS, or empty vector (VEH) cells in the presence or absence of MPL. (D) Myeloid colony formation using MNCs from normal controls (n = 5), CALR-mutated patients (n = 5), and JAK2V617F patients (n = 5). Cells were plated in methylcellulose with varying LCL-161 concentrations. Colonies were counted from each plate and normalized to 0 µM LCL-161. Error bar represent mean values ± SEM.